Imperative Care has announced the closing of US$100 million in oversubscribed convertible note financing.
The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors in partnership with existing investor Catalio Capital Management. New investors Longaeva Partners and Brown Advisory also participated in the financing, as did existing investors Ally Bridge Group and Bain Capital Life Sciences.
Additionally, Imperative Care has announced the appointment of Evan Melrose, chief executive officer (CEO) of Elevage Medical Technologies—and a seasoned medtech investor and healthcare innovator—to its board of directors.
Proceeds from the financing will support the continued commercialisation of Imperative Care’s stroke and vascular thrombectomy portfolios, as stated in a press release. Said proceeds will also be used for investments in next-generation and new product development, including the Telos robotic platform, as well as clinical evidence generation to further demonstrate the impact of these technologies on patient outcomes, the release adds.
“This financing is a reflection of the strong momentum we have built, and the confidence our investors—new and existing—have in our vision,” said Fred Khosravi, chairman and CEO of Imperative Care. “We are expanding access to lifesaving technologies for patients at the most critical moments of their lives, and this capital positions us to continue driving forward on that mission across stroke, vascular, and beyond.”
